PNC-27 protocol · PepGuide

The guide doesn't list a dosing protocol for this one. See the details below.

What to expect

Unknown in humans. Selective cancer-cell killing in the lab has not been validated as safe or effective in people.

Men & women

Unisex experimental anticancer peptide, no human data, no sex-specific dosing. A research compound, not a therapy.

Recommended mixes

Vial	Water	Strength
5 mg	2.5 mL	2 mg/mL

5 mg: Store cold/dark. No validated human dose.

Storage

PowderFreeze-dried: -20°F or colder ideal.
MixedReconstituted: refrigerate, short-dated, dark.

Don't use if: Use as a substitute for evidence-based cancer treatment · Pregnancy and lactation · Any self-administration for a serious diagnosis

Stop if you notice

This should not be self-administered for cancer
Seek proper oncologic evaluation for any cancer concern

Side effects

Unknown in humans. Membrane-disrupting mechanism carries unquantified risk to any HDM-2-expressing or stressed cells.

Drug interactions

Unknown in humans. Could interfere with real cancer therapy if misused, do not substitute.

Labs

Not applicable for self-use; oncology is managed by specialists

What these labs mean →

Warnings

No human trials; FDA-flagged as unapproved with no established safety. Membrane-lytic mechanism, unquantified off-target risk in humans. Cancer requires proper oncologic care, this is not a therapy. Quality and identity of research material vary widely.

Patient education

An intriguing preclinical anticancer mechanism, with zero human safety data. The FDA has warned against unapproved PNC-27 products. Cancer requires evidence-based treatment, do not rely on a research peptide. Included for completeness, not endorsement.

These apply on top of the universal safety rules.

Pairs well with

N/A

not a stacking compound; cancer care belongs with an oncologist

Avoid with

Use as a cancer treatment in place of evidence-based care

Pregnancy

Any self-administration for a serious diagnosis

What it does

All evidence is preclinical (cell/animal).

PNC-27 is a synthetic 32-amino-acid peptide combining a p53 (residues 12–26) HDM-2-binding domain with a membrane-penetrating domain. It binds membrane-expressed HDM-2 on cancer cells, forming transmembrane pores that cause rapid tumor-cell necrosis and mitochondrial disruption; selectively, because normal cells don't express membrane HDM-2.

Protocol

No established human protocol. All data are preclinical; the FDA has flagged PNC-27 products as unapproved with no established safety. Included for catalog completeness only, this is not a treatment, and cancer requires real oncologic care.

Important: cancer is a life-threatening disease that demands evidence-based oncology. A research peptide with no human trials is not a substitute. Self-treating cancer with PNC-27 instead of proven therapy is dangerous. This page documents the compound; it does not endorse use.

Supply math

Not applicable, no validated human dosing. Research compound only.

References

PubMed pmc clinicaltrials.gov

From the guide, page 76.